Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on FLOWGROUP PLC. We currently have 22 research reports from 3 professional analysts.
|09Feb17 07:00||RNS||MicroCHP Feed-in Tariff (FIT) update|
|13Jan17 16:15||RNS||Holding(s) in Company|
|05Dec16 07:00||RNS||Reiteration of hedging strategy for energy prices|
|05Sep16 07:00||RNS||Half-year Report|
|23Aug16 15:26||RNS||Notice of Results|
Frequency of research reports
Research reports on
Small Cap Breakfast
08 Feb 17
Arix Bioscience — Intention to float on the main market from the global healthcare and life science Company supporting medical innovation. Raised £52m in Feb 16 with investors including Woodford Investment Management Ramsdens Holdings –Schedule One from the financial services provider and retailer, operating in the core business segments of foreign currency exchange, pawnbroking loans, precious metals buying and selling and retailing of second hand and new jewellery. Expected admission to AIM 15 Feb raising circa £15.6m. Expected mkt cap £26.5m.
Strategic review of mCHP division continues
16 Nov 16
After the impromptu appointment of Prime Minister Theresa May and her Cabinet in July, alongside ongoing distractions from BREXIT, then I guess it was inevitable there would be some slippage in ministerial decision making. Indeed, it appears the Department for Business, Energy and Industrial Strategy (or BEIS, formerly DECC) has been duly affected, and may not now reach a final verdict on its proposal to reduce the number of mCHP boiler installations that can benefit from Feed-in-Tariffs (FiTs) until early next year (from Q4’16 previously).
Spearheading the shift into digital power
05 Sep 16
Ever thought how Britain’s energy infrastructure will cope in the future with rising demand from electric vehicles, whilst at the same time having to meet stricter emissions standards and compensate for the retirement of all coal-fired power stations by 2030 (see below)? Well, the answer lies in ‘smart grid’ solutions - combining the latest advanced digital technology with domestic micro generation, renewables (eg solar, wind, tidal) and large-scale storage systems.
H1 2016 results
05 Sep 16
Flow has announced its H1 2016 results and provided an operational update on its business. The results show good revenue growth (£41.8m for H1 versus £40.4m for the whole of 2015, driven by gains in the Energy segment) and continued net cash (£9.2m). A loss was reported overall given the growth phase that the company is in. Operationally, Energy continues to grow strongly – customer accounts are now up to 255k (from 100k at the start of 2016), and the company is also rolling out a third-party boiler offering as part of its broader smart heating strategy. This is from Holland’s Intergas, has now begun being sold to customers, and is planned to complement the boiler range from Daikin that will begin to be available towards the end of 2016. This is an important development in increasing customer choice and leveraging the installer network.
20 Feb 17
Hayward Tyler Group* (HAYT): Trading update and financial position (CORP) | Petra Diamonds (PDL): Interim results (BUY) | Gemfields* (GEM): Interim results (CORP) | Premaitha Health* (NIPT): Middle East momentum (CORP) | Sound Energy (SOU): Acquisition update and TE-8 well spud (HOLD) | Proactis* (PHD): Interim trading on track (CORP) | 7digital* (7DIG): Automotive contract win (CORP)
21 Feb 17
Lighthouse Group* (LGT): Middle Britain growth (CORP) | Utilitywise* (UTW): Double-digit sales growth (CORP) | Trakm8* (TRAK): Earnings expectations cut again (CORP) | dotDigital* (DOTC): Myriad growth opportunities (CORP) | Artilium* (ARTA): Five-year Telenet deal secured and prepaid (CORP) | Netcall* (NET): Cloud investment pays off (CORP)
N+1 Singer - Small-cap quantitative research - New quality style screen + 11 quality focus stocks
09 Feb 17
We introduce our fourth and final style screen representing “quality”. This screens for stocks with the best combination of high returns on capital/equity, EBIT margins and operating cash-flow conversion rates. These criteria should help us monitor how strong underlying returns translate into share price performance over time and under varying market conditions. The screen selects the “best” 25 stocks from our universe of just over 500 stocks and, as usual, we focus on a shorter list of stocks we cover or otherwise know and believe to be particularly interesting. We provide brief investment summaries on these focus stocks on pages 4 – 9. We will monitor performance and refresh the screen in approximately 3-4 months time.
The Slide Rule
12 Jan 17
What is The Slide Rule? The Slide Rule has been designed to dramatically simplify the identification of the best companies in the UK small/mid-cap sector by making a quantitative assessment of the relative potential of each company. At its core, The Slide Rule aims to identify those companies that create genuine shareholder value through strong returns on capital and solid growth, but also present a value opportunity with the potential tailwind of earnings momentum. Companies are assessed within a Quality, Value, Growth and Momentum (QVGM) framework.
Time to go over weight
24 Feb 17
We believe equity investors are taking an unnecessarily cautious stance on the construction sector. Forward looking indicators (e.g. consumer confidence, construction PMIs and housing starts) point to a stable market and recent sales LFL are particularly encouraging (e.g. Marshalls). Near term margins may suffer temporary distortions as inflationary pressures build. However, history has shown that modest input cost inflation is actually a positive for earnings growth in the sector. Therefore, as we move into 2018, margin trends are likely to surprise on the upside.
N+1 Singer - Morning Song 22-02-2017
22 Feb 17
CORETX (COR LN) Contract wins and new Lifestyle facility | Gooch & Housego (GHH LN) Solid Q1 trading plus earnings enhancing acquisition of StingRay Optics | NCC Group (NCC LN) Further issues in Assurance | PCI-PAL (PCIP LN) Strong H1 underpins positive outlook | UBM (UBM LN) Results | Verona Pharma (VRP LN) Phase IIa RPL554 add-on trial to tiotropium commenced